Annals of Oncology 14:1399-1405, 2003
© 2003 European Society for Medical Oncology
Original Paper |
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases
1 Université Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium; 2 Department of Obstetrics and Gynaecology, University Hospital, Heidelberg, Germany; 3 Department of Clinical Chemotherapy, Cancer Research Center, Moscow, Russia; 4 Krankenhaus der Barmherzigen Brueder, Onkologische Ambulanz, Regensburg; 5 Mutterhaus der Borromaeerinnen, Trier, Germany; 6 Cancer Research Center, Department of Chemotherapy, Moscow, Russia; 7 F. Hoffmann-La Roche Ltd, Basel, Switzerland; 8 F. Hoffmann-La Roche Inc., Nutley, NJ, USA
Received 23 January 2003; revised 26 March 2003; accepted 14 May 2003
Background:
This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with placebo as intravenous (i.v.) therapy in metastatic bone disease due to breast cancer.
Patients and methods:
A total of 466 patients were randomised to receive placebo (n = 158), or 2 mg (n = 154) or 6 mg (n = 154) ibandronate every 3–4 weeks for up to 2 years. The primary efficacy parameter was the number of 12-week periods with new bone complications, expressed as the skeletal morbidity period rate (SMPR). Bone pain, analgesic use and safety were evaluated monthly.
Results
SMPR was lower in both ibandronate groups compared with the placebo group; the difference was statistically significant for the ibandronate 6 mg group (P = 0.004 versus placebo). Consistent with the SMPR, ibandronate 6 mg significantly reduced the number of new bone events (by 38%) and increased time to first new bone event. Patients on ibandronate 6 mg also experienced decreased bone pain scores and analgesic use. Treatment with ibandronate was well tolerated.
Conclusions:
These results indicate that 6 mg i.v. ibandronate is effective and safe in the treatment of bone metastases from breast cancer.
Key words: bisphosphonate, bone metastases, breast cancer, ibandronate, pain, radiotherapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, et al. Third consensus on medical treatment of metastatic breast cancer Ann. Onc., November 1, 2009; 20(11): 1771 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Van den Wyngaert, M. T. Huizing, E. Fossion, and J. B. Vermorken Bisphosphonates in Oncology: Rising Stars or Fallen Heroes Oncologist, February 1, 2009; 14(2): 181 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Ripamonti, M. Maniezzo, T. Campa, E. Fagnoni, C. Brunelli, G. Saibene, C. Bareggi, L. Ascani, and E. Cislaghi Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan Ann. Onc., January 1, 2009; 20(1): 137 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Drake, B. L. Clarke, and S. Khosla Bisphosphonates: Mechanism of Action and Role in Clinical Practice Mayo Clin. Proc., September 1, 2008; 83(9): 1032 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. von Moos, C. B. Caspar, B. Thurlimann, R. Angst, R. Inauen, R. Greil, B. Bergstrom, K. Schmieding, and M. Pecherstorfer Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study Ann. Onc., July 1, 2008; 19(7): 1266 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann. Onc., March 1, 2008; 19(3): 420 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bergner, D. M. Henrich, M. Hoffmann, A. Honecker, G. Mikus, B. Nauth, D. Nagel, and M. Uppenkamp Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function J. Clin. Pharmacol., August 1, 2007; 47(8): 942 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J-J Body, M Lichinitser, S Tjulandin, P Garnero, and B Bergstrom Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases Ann. Onc., July 1, 2007; 18(7): 1165 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gridelli The Use of Bisphosphonates in Elderly Cancer Patients Oncologist, January 1, 2007; 12(1): 62 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Clemons, G. Dranitsaris, W. S. Ooi, G. Yogendran, T. Sukovic, B. Y.L. Wong, S. Verma, K. I. Pritchard, M. Trudeau, and D. E.C. Cole Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy J. Clin. Oncol., October 20, 2006; 24(30): 4895 - 4900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-J. Body Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin. Cancer Res., October 15, 2006; 12(20): 6258s - 6263s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cameron, R. Bell, M. Aapro, and C. Zielinski What Are the Current Standards of Care and Recent Developments in the Management of Breast Cancer? Oncologist, September 1, 2006; 11(suppl_1): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
A. H.G. Paterson The Role of Bisphosphonates in Early Breast Cancer Oncologist, September 1, 2006; 11(suppl_1): 13 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cameron, M. Fallon, and I. Diel Ibandronate: Its Role in Metastatic Breast Cancer Oncologist, September 1, 2006; 11(suppl_1): 27 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Botteman, V. Barghout, J. Stephens, J. Hay, J. Brandman, and M. Aapro Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases Ann. Onc., July 1, 2006; 17(7): 1072 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tanvetyanon and P. J. Stiff Management of the adverse effects associated with intravenous bisphosphonates Ann. Onc., June 1, 2006; 17(6): 897 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-J. Body, T. Facon, R. E. Coleman, A. Lipton, F. Geurs, M. Fan, D. Holloway, M. C. Peterson, and P. J. Bekker A Study of the Biological Receptor Activator of Nuclear Factor-{kappa}B Ligand Inhibitor, Denosumab, in Patients with Multiple Myeloma or Bone Metastases from Breast Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1221 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Clemons, G. Dranitsaris, D. Cole, and M. C. Gainford Too Much, Too Little, Too Late to Start Again? Assessing the Efficacy of Bisphosphonates in Patients with Bone Metastases from Breast Cancer. Oncologist, January 1, 2006; 11(3): 227 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Guarneri, S. Donati, M. Nicolini, S. Giovannelli, R. D'Amico, and P. F. Conte Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 Years Oncologist, November 1, 2005; 10(10): 842 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bell Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data Oncologist, October 1, 2005; 10(suppl_1): 8 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Jackson Renal Safety of Ibandronate Oncologist, October 1, 2005; 10(suppl_1): 14 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. von Moos Bisphosphonate Treatment Recommendations for Oncologists Oncologist, October 1, 2005; 10(suppl_1): 19 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kohno, K. Aogi, H. Minami, S. Nakamura, T. Asaga, Y. Iino, T. Watanabe, C. Goessl, Y. Ohashi, and S. Takashima Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial J. Clin. Oncol., May 20, 2005; 23(15): 3314 - 3321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Coleman Bisphosphonates in breast cancer Ann. Onc., May 1, 2005; 16(5): 687 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Jackson Safety and Compliance of Intravenous and Oral Dosing Regimens Oncologist, May 1, 2005; 10(5): 313 - 314. [Full Text] [PDF]
|
|
|
|
|
|
P. Conte and V. Guarneri In Response to Jackson Letter to the Editor Regarding "Safety of Intravenous and Oral Bisphosphonates and Compliance with Dosing Regimens" Oncologist, May 1, 2005; 10(5): 315 - 316. [Full Text] [PDF]
|
|
|
|
 |
|
 M. C Gainford, G. Dranitsaris, and M. Clemons Recent developments in bisphosphonates for patients with metastatic breast cancer BMJ, April 2, 2005; 330(7494): 769 - 773. [Full Text] [PDF]
|
|
|
|
 |
|
 H. K.W. Kim, T. S. Randall, H. Bian, J. Jenkins, A. Garces, and F. Bauss Ibandronate for Prevention of Femoral Head Deformity After Ischemic Necrosis of the Capital Femoral Epiphysis in Immature Pigs J. Bone Joint Surg. Am., March 1, 2005; 87(3): 550 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Westermann Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial Ann. Onc., March 1, 2005; 16(3): 513 - 513. [Full Text] [PDF]
|
|
|
|
|
|
I. J. Diel and R. Bergner Re: Berenson J, Hirschberg R. Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid Oncologist, January 1, 2005; 10(1): 82 - 83. [Full Text] [PDF]
|
|
|
|
|
|
J. Berenson and R. Hirschberg In Response to Diel I, Bergner R. Letter to the Editor of The Oncologist Re: Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid Oncologist, January 1, 2005; 10(1): 84 - 87. [Full Text] [PDF]
|
|
|
|
|
|
I. Mancini, J.-C. Dumon, and J.-J. Body Efficacy and Safety of Ibandronate in the Treatment of Opioid-Resistant Bone Pain Associated With Metastatic Bone Disease: A Pilot Study J. Clin. Oncol., September 1, 2004; 22(17): 3587 - 3592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kerr A word in your ear: the 2004 Annals of Oncology prizes Ann. Onc., September 1, 2004; 15(9): 1303 - 1304. [Full Text] [PDF]
|
|
|
|
|
|
J. Barrett, E. Worth, F. Bauss, and S. Epstein Ibandronate: A Clinical Pharmacological and Pharmacokinetic Update J. Clin. Pharmacol., September 1, 2004; 44(9): 951 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Coleman Bisphosphonates: Clinical Experience Oncologist, September 1, 2004; 9(suppl_4): 14 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Conte and V. Guarneri Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens Oncologist, September 1, 2004; 9(suppl_4): 28 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Berenson and R. Hirschberg Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid Oncologist, June 1, 2004; 9(3): 319 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rizzoli Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer Ann. Onc., May 1, 2004; 15(5): 700 - 701. [Full Text] [PDF]
|
|
|
|
|
|
D. Tripathy, M. Lichinitzer, A. Lazarev, S. A. MacLachlan, J. Apffelstaedt, M. Budde, and B. Bergstrom Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial Ann. Onc., May 1, 2004; 15(5): 743 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Westermann Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann. Onc., March 1, 2004; 15(3): 537 - 538. [Full Text] [PDF]
|
|